Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

3.470 +0.160 (+4.83%)
Streaming Delayed Price Updated: 1:47 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data
The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart. 
Via Stocktwits
Earnings Scheduled For May 8, 2025
Via Benzinga
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Compass Pathways Stock Is Plunging Today: What's Going On?
COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it. 
Via Stocktwits
Crude Oil Falls 1%; US Services PMI Declines In June
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Why Is Compass Pathways Stock Trading Lower On Monday?
Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment 
Via Benzinga
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results
Via Benzinga
Topics Stocks
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
From Compass Pathfinder Limited
Via Business Wire
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
From Compass Pathfinder Limited
Via Business Wire
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Via The Motley Fool
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
More People are Microdosing Psychedelics to Ease the Challenges of Parenting
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.